kerendia market size forecast and market insight

“KERENDIA Market Size, Forecast, and Market Insight - 2032” report provides comprehensive insights about KERENDIA for Chronic Kidney Disease (CKD) in the seven major markets. A detailed picture of the KERENDIA for CKD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the KERENDIA for CKD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KERENDIA market forecast analysis for CKD in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in CKD.

Drug Summary

KERENDIA is a nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes. 

Mechanism of action

Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR), which is activated by aldosterone and cortisol and regulates gene transcription. Finerenone blocks MR-mediated sodium re-absorption and MR overactivation in epithelial (e.g., kidney) and nonepithelial (e.g., heart and blood vessels) tissues. MR overactivation contributes to fibrosis and inflammation. Finerenone has a high potency and selectivity for the MR and has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors.

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the KERENDIA description, mechanism of action, dosage and administration, research and development activities in Chronic Kidney Disease (CKD).
• Elaborated details on KERENDIA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the KERENDIA research and development activities in CKD across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around KERENDIA.
• The report contains forecasted sales of KERENDIA for CKD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for CKD.
• The report also features the SWOT analysis with analyst views for KERENDIA in CKD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KERENDIA Analytical Perspective by DelveInsight

In-depth KERENDIA Market Assessment

This report provides a detailed market assessment of KERENDIA for Chronic Kidney Disease (CKD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

KERENDIA Clinical Assessment

The report provides the clinical trials information of KERENDIA for CKD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Chronic Kidney Disease (CKD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KERENDIA dominance.
• Other emerging products for CKD are expected to give tough market competition to KERENDIA and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KERENDIA in CKD.
• Our in-depth analysis of the forecasted sales data of KERENDIA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KERENDIA in CKD. 

Key Questions

• What is the product type, route of administration and mechanism of action of KERENDIA?
• What is the clinical trial status of the study related to KERENDIA in Chronic Kidney Disease (CKD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KERENDIA development?
• What are the key designations that have been granted to KERENDIA for CKD?
• What is the forecasted market scenario of KERENDIA for CKD?
• What are the forecasted sales of KERENDIA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to KERENDIA for CKD?
• Which are the late-stage emerging therapies under development for the treatment of CKD?